Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34:2182–90. https://doi.org/10.1200/JCO.2015.65.7759.

Article  PubMed  Google Scholar 

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–90. https://doi.org/10.1016/j.juro.2017.11.095.

Article  PubMed  Google Scholar 

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–29. https://doi.org/10.1016/j.eururo.2016.08.003.

Article  PubMed  Google Scholar 

Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010;8:145. https://doi.org/10.6004/jnccn.2010.0010.

Article  PubMed  Google Scholar 

Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D’Amico AV, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. JAMA. 2019;321:704–6. https://doi.org/10.1001/jama.2018.19941.

Article  PubMed  PubMed Central  Google Scholar 

Pooli A, Salmasi A, Faiena I, Lenis AT, Johnson DC, Lebacle C, et al. Variation in surgical treatment patterns for patients with prostate cancer in the United States: do patients in academic hospitals fare better? Urol Oncol Semin Orig Investig. 2019;37:63–70. https://doi.org/10.1016/j.urolonc.2018.10.018.

Article  Google Scholar 

Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol J Am Soc Clin Oncol. 2013;31:2991–7. https://doi.org/10.1200/JCO.2012.47.0302.

Article  Google Scholar 

Katz JE, Chinea FM, Patel VN, Balise RR, Venkatramani V, Gonzalgo ML, et al. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study. Prostate Cancer Prostatic Dis. 2018;21:533–8. https://doi.org/10.1038/s41391-018-0057-6.

Article  PubMed  Google Scholar 

Deka R, Parsons JK, Simpson DR, Riviere P, Nalawade V, Vitzthum LK, et al. African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. Prostate Cancer Prostatic Dis. 2020;23:581–8. https://doi.org/10.1038/s41391-020-0230-6.

Article  PubMed  Google Scholar 

Maurice MJ, Sundi D, Schaeffer EM, Abouassaly R. Risk of pathological upgrading and up staging among men with low risk prostate cancer varies by race: results from the National Cancer Database. J Urol. 2017;197:627–31. https://doi.org/10.1016/j.juro.2016.08.095.

Article  PubMed  Google Scholar 

Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology. 2014;84:1434–41. https://doi.org/10.1016/j.urology.2014.08.039.

Article  PubMed  Google Scholar 

Dinizo M, Shih W, Kwon YS, Eun D, Reese A, Giusto L, et al. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget. 2018;9:21359–65. https://doi.org/10.18632/oncotarget.25103.

Article  PubMed  PubMed Central  Google Scholar 

Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015;67:451–7. https://doi.org/10.1016/j.eururo.2014.03.026.

Article  PubMed  Google Scholar 

Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–34. https://doi.org/10.7326/0003-4819-157-2-201207170-00459.

Article  PubMed  Google Scholar 

Halpern JA, Shoag JE, Artis AS, Ballman KV, Sedrakyan A, Hershman DL, et al. National trends in prostate biopsy and radical prostatectomy volumes following the US Preventive Services Task Force guidelines against prostate-specific antigen screening. JAMA Surg. 2017;152:192–8. https://doi.org/10.1001/jamasurg.2016.3987.

Article  PubMed  Google Scholar 

Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J Natl Cancer Inst. 2021;113:64–71. https://doi.org/10.1093/jnci/djaa068.

Article  PubMed  Google Scholar 

Deka R, Courtney PT, Parsons JK, Nelson TJ, Nalawade V, Luterstein E, et al. Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA. 2020;324:1747–54. https://doi.org/10.1001/jama.2020.17020.

Article  PubMed  PubMed Central  Google Scholar 

Vigneswaran HT, Mittelstaedt L, Crippa A, Eklund M, Vidal A, Freedland SJ, et al. Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022;25:165–73. https://doi.org/10.1038/s41391-021-00425-1.

Article  PubMed  Google Scholar 

Iremashvili V, Soloway MS, Rosenberg DL, Manoharan M. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol. 2012;187:1594–9. https://doi.org/10.1016/j.juro.2011.12.082.

Article  PubMed  Google Scholar 

Sundi D, Faisal FA, Trock BJ, Landis PK, Fen Z, Ross AE, et al. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology. 2015;85:155–60. https://doi.org/10.1016/j.urology.2014.08.014.

Article  PubMed  Google Scholar 

Tosoian JJ, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN, et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol. 2020;77:675–82. https://doi.org/10.1016/j.eururo.2019.12.017.

Article  PubMed  Google Scholar 

Ritch CR, Morrison BF, Hruby G, Coard KC, Mayhew R, Aiken W, et al. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison. BJU Int. 2013;111:E186–90. https://doi.org/10.1111/j.1464-410X.2012.11540.x.

Article  CAS  PubMed  Google Scholar 

Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, et al. Prostate cancer genomic-risk differences between African-American and White men across Gleason scores. Eur Urol. 2019;75:1038–40. https://doi.org/10.1016/j.eururo.2019.01.010.

Article  PubMed  Google Scholar 

Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, et al. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:125–36. https://doi.org/10.1038/s41391-018-0083-4.

Article  PubMed  Google Scholar 

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22. https://doi.org/10.1016/S0140-6736(16)32401-1.

Article  PubMed  Google Scholar 

Shungu N, Diaz VA, Perkins S, Kulshreshtha A. Physician attitudes and self-reported practices toward prostate cancer screening in Black and White men. Fam Med. 2022;54:30–7. https://doi.org/10.22454/FamMed.2022.474827.

Article  PubMed  Google Scholar 

Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, et al. Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy. J Urol. 2016;196:1408–14. https://doi.org/10.1016/j.juro.2016.06.086.

Article  PubMed  PubMed Central  Google Scholar 

Schreiber D, Chhabra A, Rineer J, Weedon J, Schwartz D. A population-based study of men with low-volume low-risk prostate cancer: does African-American race predict for more aggressive disease? Clin Genitourin Cancer. 2015;13:e259–64. https://doi.org/10.1016/j.clgc.2015.02.006.

Article  PubMed  Google Scholar 

Al Awamlh BAH, Patel N, Ma X, Calaway A, Ponsky L, Hu JC, et al. Variation in the Use of active surveillance for low-risk prostate cancer across US census regions. Front Oncol. 2021;11. https://www.frontiersin.org/articles/10.3389/fonc.2021.644885.

Washington SL III, Jeong CW, Lonergan PE, Herlemann A, Gomez SL, Carroll PR, et al. Regional variation in active surveillance for low-risk prostate cancer in the US. JAMA Netw Open. 2020;3:e2031349. https://doi.org/10.1001/jamanetworkopen.2020.31349.

Article  PubMed  PubMed Central  Google Scholar 

Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV. Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Netw Open. 2023;6:e231439.

Article  PubMed  PubMed Central  Google Scholar